SWM
CRSP icon

Spire Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Spire Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
2,718
+500
+23% +$26.4K ﹤0.01% 872
2026
Q1 		$106K Buy
2,218
+650
+41% +$34.3K ﹤0.01% 945
2025
Q4 		$82.2K Hold
1,568
– – ﹤0.01% 1043
2025
Q3 		$102K Sell
1,568
-650
-29% -$37.3K ﹤0.01% 984
2025
Q2 		$108K Buy
2,218
+548
+33% +$21.2K ﹤0.01% 942
2025
Q1 		$56.8K Sell
1,670
-300
-15% -$12.7K ﹤0.01% 1233
2024
Q4 		$77.5K Buy
1,970
+1,482
+304% +$70K ﹤0.01% 1132
2024
Q3 		$22.9K Sell
488
-15
-3% -$761 ﹤0.01% 1402
2024
Q2 		$27.2K Sell
503
-2,664
-84% -$154K ﹤0.01% 1327
2024
Q1 		$216K Buy
3,167
+2,713
+598% +$194K ﹤0.01% 749
2023
Q4 		$28.1K Sell
454
-598
-57% -$33.1K ﹤0.01% 1411
2023
Q3 		$47.8K Buy
1,052
+259
+33% +$13.4K ﹤0.01% 1188
2023
Q2 		$44.5K Buy
793
+400
+102% +$22.7K ﹤0.01% 1244
2023
Q1 		$17.8K Buy
393
+20
+5% +$971 ﹤0.01% 1670
2022
Q4 		$15K Hold
373
– – ﹤0.01% 1474
2022
Q3 		$24K Hold
373
– – ﹤0.01% 1247
2022
Q2 		$23K Buy
+373
New +$21.9K ﹤0.01% 1605
2022
Q1 		– Sell
-1,090
Closed -$83K – 2585
2021
Q4 		$83K Buy
1,090
+990
+990% +$86.5K ﹤0.01% 1488
2021
Q3 		$11K Hold
100
– – ﹤0.01% 2060
2021
Q2 		$16K Sell
100
-288
-74% -$35K ﹤0.01% 1961
2021
Q1 		$44K Buy
+388
New +$58.6K ﹤0.01% 1786

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Spire Wealth Management's CRSP Position: Q2 2026 in Review

Spire Wealth Management increased its CRISPR Therapeutics (CRSP) stake by 23% in Q2 2026, buying an estimated $26.4K and bringing the position to 2,718 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #872.

Spire Wealth Management first reported a position in CRSP in Q1 2021 and has held it in 21 quarters since. The position peaked at $216K in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Spire Wealth Management held 2,718 shares of CRISPR Therapeutics worth $148K as of Q2 2026.
  • Spire Wealth Management bought 500 CRISPR Therapeutics shares in Q2 2026, an estimated $26.4K.
  • CRISPR Therapeutics made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #872 holding.
  • Spire Wealth Management first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Spire Wealth Management's CRISPR Therapeutics position peaked at $216K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.